The link between sleep disorders and future risk of dementia: a systematic review and meta-analysis
Abstract
Dementia development has been linked to sleep problems, but the type and extent of this link are still unknown. The future dementia risk was examined in this systematic review and meta-analysis according to several sleep disorders. Based on 15 longitudinal studies released from 2020 up to December 2025, a thorough review and meta-analysis were carried out. These studies monitored 2,281,507 individuals from several nations for periods ranging from four to forty years. Different sleep disorders were investigated among the studies, including insomnia, sleep disturbance, excessive daytime sleepiness (EDS, and restless leg syndrome (RLS). Meta-analysis was conducted to assess the hazard ratio (HR) of the development of dementia among patients with sleep disorders. The Meta-analysis found that all-cause sleep disorders were associated with a significantly higher risk for dementia (HR: 1.13, 95% CI: 1.05–1.22, p-value=0.0082). Among different sleep disorders, EDS showed the highest risk for development dementia with HR of 1.41 (95% CI: 1.17-1.71), followed by RLS (HR: 1.29, 95% CI: 1.04–1.60), inomnia (HR: 1.19, 95 % CI: 1.06-1.35), sleeping for less than 7 hours or more than 8 hours (HR: 1.18). Poor sleep quality and difficulties in falling asleep did not show a significant correlation with the risk of dementia. The current systematic review confirmed the significant association between sleep disorders and the chance of developing future dementia. These findings indicated the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,281,507 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.